NCT07409844 (RESET C2) is a Phase 2 clinical trial of 1 Cycle of Pembrolizumab in DMMR Colorectal Cancer, sponsored by Ismail Gögenur.

Who is sponsoring NCT07409844?

NCT07409844 is sponsored by Ismail Gögenur.

What drugs are being tested in NCT07409844?

Interventions in NCT07409844: 1 Cycle of Pembrolizumab, 2 Cycles of Pembrolizumab, 3 Cycles of Pembrolizumab, Additional Cycle of Pembrolizumab.

What condition does NCT07409844 study?

NCT07409844 studies DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III, Pembrolizumab, Immunotherapy.

Is NCT07409844 still recruiting?

NCT07409844 is currently not yet recruiting. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT07409844: RESET C2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

Not yet recruiting Phase 2 Last updated 20 February 2026

What this trial tests

Phase 2 trial testing 1 Cycle of Pembrolizumab in DMMR Colorectal Cancer in 152 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
1 March 2028

1 January 2031

Quick facts

Lead sponsor	Ismail Gögenur
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	152
Start date	1 March 2026
Primary completion	1 March 2028
Estimated completion	1 January 2031
Sites	1 location across Denmark

Drugs / interventions tested

1 Cycle of Pembrolizumab — full drug profile →
2 Cycles of Pembrolizumab — full drug profile →
3 Cycles of Pembrolizumab — full drug profile →
Additional Cycle of Pembrolizumab — full drug profile →

Conditions studied

DMMR Colorectal Cancer — all drugs for DMMR Colorectal Cancer →
Colon Cancer Stage I — all drugs for Colon Cancer Stage I →
Colon Cancer Stage II/III — all drugs for Colon Cancer Stage II/III →
Pembrolizumab — all drugs for Pembrolizumab →

Sponsor

Ismail Gögenur — full company profile →

Who can join

18 and older, any sex, with DMMR Colorectal Cancer or Colon Cancer Stage I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The RESET C2 trial aims to introduce organ sparing treatment or watch-and-wait (WW) to patients with localized deficient mismatch repair (dMMR) colon cancer through use of neoadjuvant pembrolizumab. Patients will be divided into four treatment arms based on their surgical and oncologic risks. Each arm provides different intensity neoadjuvant immunotherapy regimens. Patients with complete response at disease restaging procedures will be offered non-operative management, whereas those with non-complete response will proceed to surgery ± adjuvant chemotherapy as standard of care. A WW protocol with regular disease surveillance continues over survivorship. If there is recurrence, surgery and/or appropriate oncologic therapy will be offered determined by multi-disciplinary teams. This is a national, non-randomised, investigator-initiated trial including patients from 13 hospitals across Denmark. The rationale, design, and clinical response metrics are derived from the RESET C study (NCT05662527) showing efficacy, safety and feasibility of neoadjuvant pembrolizumab in this cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for DMMR Colorectal Cancer

Currently open trials in the same condition.

NCT04301557 — PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer · Phase 2 · active not recruiting

Other Ismail Gögenur trials

Trials by the same sponsor.

NCT05740969 — Gene and Protein Expression Profiles After Treatment of Actinic Keratoses · Phase 2 · unknown
NCT05609656 — Electroporation and Immunotherapy in Metastatic Colorectal Cancer · Phase 2 · terminated
NCT05740137 — Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy · NA · completed
NCT05754229 — Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy · NA · unknown
NCT05435053 — Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07409844 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ismail Gögenur
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07409844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing